Catabasis Pharmaceuticals

Catabasis Pharmaceuticals

Catabasis Pharmaceuticals was incorporated in 2008 in Cambridge, Massachusetts, by CEO Jill Milne and CSO Michael Jirousek, who previously held roles at Sirtris and Pfizer. The firm raised over $100M from venture investors including Fidelity, Novartis Venture Fund, and Roche Venture Fund, and went public on Nasdaq in 2014. Its singular platform focused on exploiting the intersection of metabolic pathways and inflammation, but commercial traction never materialized. The company's principal asset was edasalonexent, an oral small molecule designed to block NF-kB signaling in Duchenne muscular dystrophy. Clinical data from a Phase 3 trial, announced in late 2020, showed no significant improvement in functional outcomes compared to placebo (per Reuters, November 2020). Catabasis also explored edasalonexent in other rare conditions, including methylmalonic acidemia and familial chylomicronemia syndrome, but those programs were terminated post–trial failure. At peak in 2015, Catabasis employed approximately 30 people. The firm maintained a single Boston office. In early 2021, biotech Evelo Biosciences announced acquisition of Catabasis in an all-stock deal valued at $5.5M at close, including assumption of a $40M reverse merger structure (per Xconomy, February 2021). That transaction effectively dissolved Catabasis as an independent entity. Catabasis exemplifies a structural biotech pattern: a single-drug platform designed to address a high-need rare disease, funded by top-tier crossover investors, but fatally exposed to the binary outcome of a pivotal trial. Unlike a diversified biotech conglomerate, Catabasis had no pipeline cushion, making its 2021 reverse merger the only viable exit.